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Inflammation is an important risk factor for colorectal cancer (CRC).  Non-steroidal anti-inflammatory 
drugs (NSAIDs), such as aspirin or ibuprofen, inhibit inflammation.  The use of NSAIDs has been 
shown to reduce colorectal cancer risk and mortality.  Similarly, genetic variation in genes related to 
inflammation pathways also affects colorectal cancer risk and mortality.  In a recent report in 
Carcinogenesis, Ms. Alexa Resler and Dr. Cornelia Ulrich and colleagues in the Public Health 
Sciences Division evaluated whether genetic variants in NSAID metabolism pathways may affect the 
chemopreventive capacity of NSAID use for colorectal cancer.  Analyses revealed genetic variants in 
two genes that were associated with rectal cancer risk.  They also found an interaction between one 
of these genes and NSAID use for the risk of colorectal cancer, raising the prospect of targeted 
NSAID use for cancer prevention. 
NSAIDs act to reduce inflammation by inhibiting the activity of cyclooxygenase enzymes that control 
the synthesis of prostaglandins and thromboxanes (see figure).  This study, said lead author Resler, 
"comprehensively assessed whether variation in prostaglandin synthesis and related pathways 
influences colorectal cancer risk."  To do so, the authors identified a set of 192 single nucleotide 
polymorphisms (SNPs) in and around 17 genes involved in prostaglandin synthesis and related 
pathways.  These variants were genotyped in 1600 CRC cases and 2600 sibling controls in the 
Colon Cancer Family Registry.  The investigators analyzed these variants for an association with 
colorectal cancer, as well as with colon and rectal cancer individually. 
While no variants were found to be associated with colon or colorectal cancer, two SNPs 
demonstrated a statistically significant association with rectal cancer.  Interestingly, the variant 
alleles in these genes had effects in opposite directions.  Participants with the variant allele in 
ALOX12 had an almost 90% increased risk of rectal cancer (odds ratio 1.87, 95% confidence 
interval 1.19 – 2.95), while participants with the variant allele in PTGER2 had an approximately 50% 
decreased risk of rectal cancer (odds ratio 0.49, 95% confidence interval 0.29-0.82).  Said senior 
author Ulrich, "these results suggest that genetic variation in genes encoding enzymes that are 
critical in the production of leukotrienes (ALOX12) and prostaglandins (PTGER2) may affect the risk 
of rectal cancer." 
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To further characterize these relationships, the authors also assessed whether any of these genetic 
associations with CRC risk were modified by pre-diagnostic use of NSAIDs.  After correcting for 
multiple comparisons, a statistically significant interaction was observed for NSAID use and another 
SNP in ALOX12 on colorectal cancer risk (p = 0.03).  Among the participants heterozygous for the 
variant allele, those reporting current NSAID use had an approximately 40% lower risk of CRC 
compared to those reporting never or former use (odds ratio 0.60, 95% confidence interval 0.42-
0.80).  This interaction was not statistically significant among participants homozygous for either the 
variant or wildtype allele. 
Overall, these results suggest that the expected protective association between NSAID intake and 
colorectal cancer risk may depend on the genetic background of an individual, raising the possibility 
for personalized prevention strategies.  Said Ulrich, "because NSAIDs are clearly cancer preventive, 
yet also carry risks of side effects, the interaction between use of NSAIDs and polymorphisms in 
ALOX12 is particularly exciting."  Moving forward from this study, said Ulrich, "our goal is the 
development of genetically targeted cancer prevention strategies with NSAIDs.  By identifying 
people who have a greater likelihood of benefitting, we can help personalize prevention." 
Other PHS investigators contributing to this project were Drs. Karen Makar, John Whitton, John 
Potter, and Polly Newcomb, as well as Mr. Michael Passarelli and Ms. Laura Heath. 
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(Image provided by Ms. Alexa Resler) 
Non-steroidal anti-inflammatory drugs (NSAIDs) act to reduce inflammation by inhibiting the 
cyclooxygenase enzymes (COX). These COX enzymes control the conversion of arachidonic acid to 
prostaglandins and thromboxane, which modulate important cellular functions related to 
inflammation. 
 
